ClinicalTrials.gg
CompletedNCT00851409OPERAUpdated Jun 26, 2018Results posted

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration

A Phase 2 interventional study of Recombinant Human C1 Inhibitor in Genetic Disorders and Hereditary Angioedema, sponsored by Pharming Technologies B.V.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-26.

Primary conditionAngioedemas, HereditaryRegistry: Genetic Diseases, InbornReclassifiedWhy we changed it
Registry
Genetic Diseases, Inborn — the first condition term the registry derived for this study.
ClinicalTrials.gg
Angioedemas, Hereditary
Why
  1. The study's listed conditions name Angioedemas, Hereditary, a narrower term within Genetic Diseases, Inborn.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. Complement C1 Inhibitor Protein · Angioedemas, Hereditary.

Enrollment
12th of 17
25 · median 32
Started
2009
the only one that year
Phase 2
2 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
4 of 17
Pharming Technologies B.V.

Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, this one is the 12th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 2, and was the 11th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About Complement C1 Inhibitor Protein

Complement C1 Inhibitor Protein: first FDA approval 2014 (Ruconest), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary as a file.
02

Study summary

Hereditary angioedema ("HAE") is a disease characterized by recurrent tissue swelling affecting various body locations. Recent literature shows that patients with frequent attacks may benefit from long-term prophylaxis. This study aims to evaluate the safety and prophylactic effect of weekly administrations of 50 IU/kg recombinant C1 Inhibitor ("rhC1INH").

03

Conditions studied

  • Genetic Disorders
  • Hereditary Angioedema

Browse trials for

04

In context

Angioedemas, Hereditary Reclassified

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

This study's enrollment of 25 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.

Browse Angioedemas, Hereditary studies →

Lead sponsor

Pharming Technologies B.V. is the lead sponsor of 22 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Compared within Angioedemas, Hereditary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged at least 18 years
  • Signed
  • Comfirmed diagnosis of HAE with baseline plasma level of functional C1INH activity of less than 50% of normal, and/or proven HAE ,mutation in C1INH gene.

Exclusion criteria

Exclusion Criteria:

  • A history of anaphylaxis or severe allergy (i.e. requiring medication) to food, proteins and/or drugs.
  • A history of allergic reactions to C1INH products or rabbit protein.
  • Any reported SAE related to study drug administration (withdrawal criterium)
  • Elevated IgE against rabbit dander (>0.35 kU/L; ImmunoCap assay; Phadia)
  • A diagnosis of acquired C1INH deficiency.
  • Woman of child bearing potential, pregnancy or breast-feeding
  • previous treatment within the last 3 months with plasma-derived C1INH
  • Any abnormality in the routine haematology, biochemistry and urinalysis
  • Any condition or treatment that in the opinion of the investigator might interfere with the evaluation of the study objectives.
  • Any changes since screening that would exclude subject based on above exclusion criteria.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Other
    Recombinant Human C1 Inhibitor

    Weekly administration of 50 IU/kg Recombinant Human C1 Inhibitor

    Drug: Recombinant Human C1 Inhibitor

Interventions

07

What researchers measure

Primary outcomes

  1. HAE Attacks/Week

    Prior to the treatment period, patients enrolled in the study, were asked about the amount of "HAE" attacks in the past 2 years, (calculated to attacks/week), this number is defined as "Historical". During the treatment period, patients received a dose of 50 IU/kg of "rhC1INH" administered by slow "IV" injection over 4 to 5 minutes, once a week during an eight week period. The amount of attacks during this period is defined as "Prophylaxis" (calculated to attacks/week).

    Time frame: 8 weeks

Secondary outcomes

  1. The Evaluation of Pharmacokinetic/ Pharmacodynamic ("PK/PD")Parameters.

    "PK/PD" parameters will be based on concentration time curves after the 1st and 8th "rhC1INH" administration.(ratio visit 8/ visit 1, based on the area under the curve from baseline up to 4 hours after administration (AUC 0-4)

    Time frame: 8 weeks

08

Results

Posted Jan 31, 2013

Participant flow

Patients with a history of frequent attacks, defined as "HAE" attacks occurring at least every two weeks were included in the study.

Participant flow — Overall Study
MilestoneRecombinant Human C1 Inhibitor
Started25
Completed25
Not completed0

Outcome measures

PrimaryHAE Attacks/Week

Prior to the treatment period, patients enrolled in the study, were asked about the amount of "HAE" attacks in the past 2 years, (calculated to attacks/week), this number is defined as "Historical". During the treatment period, patients received a dose of 50 IU/kg of "rhC1INH" administered by slow "IV" injection over 4 to 5 minutes, once a week during an eight week period. The amount of attacks during this period is defined as "Prophylaxis" (calculated to attacks/week).

Time frame:
8 weeks
Reported as:
Mean · attacks/week
HAE Attacks/Week
attacks/weekRecombinant Human C1 Inhibitor
Historical0.9 (0.51 to 1.30)
Prophylaxis0.4 (0.27 to 0.56)
SecondaryThe Evaluation of Pharmacokinetic/ Pharmacodynamic ("PK/PD")Parameters.

"PK/PD" parameters will be based on concentration time curves after the 1st and 8th "rhC1INH" administration.(ratio visit 8/ visit 1, based on the area under the curve from baseline up to 4 hours after administration (AUC 0-4)

Time frame:
8 weeks
Reported as:
Geometric mean · ratio
The Evaluation of Pharmacokinetic/ Pharmacodynamic ("PK/PD")Parameters.
ratioRecombinant Human C1 Inhibitor
Functional C1 Inhibitor level1.06 (0.98 to 1.14)
Antigenic C1 Inhibitor level1.02 (0.91 to 1.15)
C4 level1.00 (0.74 to 1.33)

Adverse events

Collected over Treatment emergent adverse events ("TEAEs") were defined as events with start from onset of study drug administration. All Serious Adverse Events("SAEs")are listed.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Recombinant Human C1 Inhibitor—2/25 (8%)2/25 (8%)
Most frequent serious events
Most frequent serious events
EventRecombinant Human C1 Inhibitor
AppendicitisInfections and infestations1/25
Laryngeal edemaRespiratory, thoracic and mediastinal disorders1/25
Most frequent other events
Most frequent other events
EventRecombinant Human C1 Inhibitor
Anaemia-mildBlood and lymphatic system disorders1/25
Anaemia-moderateBlood and lymphatic system disorders1/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Recombinant Human C1 Inhibitor
<=18 years0
Between 18 and 65 years25
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Recombinant Human C1 Inhibitor
Female20
Male5
09

Study locations

2 sites
  • For information on sites, please contact Pharming Technologies
    Leiden, Netherlands
  • Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department
    Târgu-Mureş, 541103, Romania
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2009
First posted
Feb 26, 2009
Start
Jun 2009
Primary completionActual
Mar 2010
CompletionActual
Apr 2010
Results first posted
Jan 31, 2013
Last update
Jun 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00851409
Responsible party
Sponsor
First posted
Feb 26, 2009
Start date
Jun 2009
Primary completion
Mar 2010
Completion
Apr 2010
Results posted
Jan 31, 2013
Last update
Jun 26, 2018

Study contacts

Bruno Giannetti, MD
study chair · COO Pharming

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)

Start the discussion